Cellular retinoic acid binding protein II as a marker for breast cancer
AssigneeRoche Diagnostics Operations, Inc.
InventorsGabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
Life of this patent
Estimating the term…
Abstract
The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.
Claims21
A method of detecting cellular retinoic acid-binding protein II in a liquid biological sample, said method comprising the step of:
- (a) providing a liquid sample obtained from an individual,
- (b) contacting said sample with a specific binding agent for cellular retinoic acid-binding protein II under conditions appropriate for formation of a complex between said binding agent and the cellular retinoic acid-binding protein II;
- and
- (c) detecting said complexes.
A method for diagnosing breast cancer comprising the steps of:
- (a) providing a liquid sample obtained from an individual,
- (b) contacting said sample with a specific binding agent for cellular retinoic acid-binding protein II under conditions appropriate for formation of a complex between said binding agent and cellular retinoic acid-binding protein II, and
- (c) correlating the amount of complex formed in (b) to the diagnosis of breast cancer.
A method of monitoring the effectiveness of an anticancer therapy, said method comprising:
- (a) determining pretreatment levels of cellular retinoic acid-binding protein II in a biological sample recovered from a patient,
- (b) administering an anticancer therapy to said patient, and
- (c) determining the post treatment levels of cellular retinoic acid-binding protein II in a biological sample obtained from said patient.
An immunological kit comprising at least one specific binding agent for cellular retinoic acid-binding protein II and auxiliary reagents for measurement of cellular retinoic acid-binding protein II.
Dependencies are inferred from the claim text.